We, therefore, sought to test whether APOE genetic variation influences the association between BP and ICH recurrence risk, as well as the risk of other clinical manifestations of progressive SVD (ischaemic stroke, dementia, late-life depression and gait impairment) in a cohort of consecutive ICH survivors. This evidence concerns the gene APOE and major depressive disorder.